Spots Global Cancer Trial Database for ZD6474 Phase IIa Dose Finding Multicentre Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ZD6474 Phase IIa Dose Finding Multicentre Study
Official Title: A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
Study ID: NCT00252746
Conditions
Study Description
Brief Summary: To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Matsuyama, Ehime, Japan
Research Site, Isehara, Kanagawa, Japan
Research Site, Osakasayama, Osaka, Japan
Research Site, Toyonaka, Osaka, Japan
Research Site, Sunto-gun, Shizuoka, Japan
Research Site, Okayama, , Japan
Research Site, Tokyo, , Japan
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
